» Articles » PMID: 38136320

BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Dec 23
PMID 38136320
Authors
Affiliations
Soon will be listed here.
Abstract

At present, multiple myeloma (MM) is still an essentially incurable hematologic malignancy. Although BCMA-targeted therapies have achieved remarkable results, BCMA levels were found to be downregulated in patients with MM who relapsed after these treatments. Therefore, the search for other antigens specific to MM has become a priority. Independently of BCMA expression, G-protein-coupled receptor family C group 5 member D (GPRC5D) is mainly expressed in the plasma cells of MM patients, while it is expressed in a limited number of normal tissues. Combining MM-specific antigen GPRC5D and T-cell-mediated therapies would be a promising therapeutic strategy for MM. Recently, we constructed a new anti-GPRC5D × anti-CD3 T-cell-engaging bispecific antibody (TCB), BR109, which was capable of binding to human GPRC5D and human CD3ε. Moreover, BR109 was proven to have relatively good stability and antitumor activity. BR109 could specifically trigger T-cell-mediated cytotoxicity against many GPRC5D-positive MM cells in vitro. Meanwhile, antitumor activity was demonstrated in MM cell line xenograft mouse models with human immune cell reconstitution. These preclinical studies have formed a solid foundation for the evaluation of MM treatment efficacy in clinical trials.

Citing Articles

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins.

Lacy E, Nanjunda R, Klakamp S, Kwok D, Nemeth J, Powers G Sci Rep. 2025; 15(1):3352.

PMID: 39870691 PMC: 11772844. DOI: 10.1038/s41598-024-82288-9.


[Research progress in targeting GPRC5D for the treatment of multiple myeloma].

An J, Pan M, Ouyang H, Mi J Zhonghua Xue Ye Xue Za Zhi. 2024; 45(9):883-888.

PMID: 39414618 PMC: 11518913. DOI: 10.3760/cma.j.cn121090-20240322-00109.


Targeting GPRC5D for multiple myeloma therapy.

Zhou D, Wang Y, Chen C, Li Z, Xu K, Zhao K J Hematol Oncol. 2024; 17(1):88.

PMID: 39342286 PMC: 11439263. DOI: 10.1186/s13045-024-01611-z.

References
1.
Ishiguro T, Sano Y, Komatsu S, Kamata-Sakurai M, Kaneko A, Kinoshita Y . An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017; 9(410). DOI: 10.1126/scitranslmed.aal4291. View

2.
Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A . GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology. 2013; 18(6):348-51. DOI: 10.1179/1607845413Y.0000000079. View

3.
Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

4.
Ray U, Orlowski R . Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. Pharmaceuticals (Basel). 2023; 16(4). PMC: 10145905. DOI: 10.3390/ph16040590. View

5.
Smith E, Harrington K, Staehr M, Masakayan R, Jones J, Long T . GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019; 11(485). PMC: 7508042. DOI: 10.1126/scitranslmed.aau7746. View